Skip to main content

Table 2 Summary of costs and benefits of atezolizumab plus nab-paclitaxel versus nab-paclitaxel (base-case)

From: Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer

 

Atezolizumab/nab-paclitaxel

Nab-paclitaxel

Incremental

PFLYs

0.856

0.566

0.290

LYs

2.308

1.672

0.636

QALYs

1.255

0.895

0.361

Total Costs (S$)

173,623

56,563

117,060

 Drug and drug administration costs, first-line

148,311

36,688

111,623

 Drug and drug administration costs, subsequent-lines

8551

8230

321

 Disease monitoring and management costs

14,107

8645

5461

 Palliative care costs

2654

3000

− 345

ICER (S$ per LY gained)

  

183,965

ICER (S$ per QALY gained)

  

324,550

  1. PFLY progression-free life year, LY life year, QALY quality-adjusted life year, ICER incremental cost-effectiveness ratio